Actively Recruiting

Phase 2
Age: 40Years +
All Genders
NCT06601127

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

Led by Tianjin Institute of Pharmaceutical Research Co., Ltd · Updated on 2025-03-07

600

Participants Needed

2

Research Sites

66 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is designed to evaluate efficacy and safety of tiprogrel in the treatment of patients with acute ischemic cerebrovascular events.

CONDITIONS

Official Title

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 40 years or older
  • Acute minor ischemic stroke defined by neurological deficit with NIHSS score 5 or less and specific imaging showing artery stenosis or infarctions
  • High-risk transient ischemic attack with ABCD2 score 6 or higher and artery stenosis
  • Ability to start study drug within 24 hours of symptom onset
  • Women of childbearing potential must agree to no pregnancy from consent to 3 months after last dose
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Brain bleeding or other major brain disorders on baseline imaging
  • Isolated sensory symptoms, visual changes, or dizziness without infarction on imaging
  • Preceding modified Rankin Scale score greater than 2
  • Contraindication to antiplatelet therapy
  • Need for anticoagulation
  • Continuous use of two or more antiplatelet drugs for 3 or more days before enrollment
  • Use of heparin or oral anticoagulants within 10 days before enrollment
  • Thrombolysis or mechanical thrombectomy within 24 hours prior to enrollment
  • History of intracranial hemorrhage or amyloid angiopathy
  • History of aneurysm
  • Diagnosis or suspicion of acute coronary syndrome
  • History of asthma
  • High risk for slow heart rate (bradyarrhythmia)
  • Need for long-term NSAIDs within 8 days after randomization
  • Recent gastrointestinal bleeding or major surgery
  • Stroke or TIA caused by medical procedures
  • Planned revascularization or surgery requiring stopping study drug within 3 months
  • Severe non-cardiovascular illness with life expectancy under 3 months
  • Women pregnant, breastfeeding, or not using effective contraception
  • Current participation in experimental drug or device study
  • Participation in another experimental study within 30 days
  • Unable to understand or follow study procedures due to mental or emotional disorders
  • Hemoglobin below 90 g/L
  • Permanent hypertension
  • Investigator's judgment of unsuitability for the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Central Hospital Affiliated to Shenyang Medical College

Shenyang, Liaoning, China

Actively Recruiting

2

Beijing Tiantan Hosptial, Capital Medical University

Beijing, China

Not Yet Recruiting

Loading map...

Research Team

X

Xiaofei Pan

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here